Related Experiment Video
Updated: Mar 31, 2026
Assessing Transmissible Spongiform Encephalopathy Species Barriers with an In Vitro Prion Protein Conversion Assay
Published on: March 10, 2015
Non-clinical development of CER-001
1Cerenis Therapeutics , Labege, France.
Insights
High-density lipoprotein (HDL) mimetic CER-001 shows promise for stabilizing cardiovascular plaques. Non-clinical data confirm CER-001 functions as a full HDL mimetic, offering potential new therapies for cardiovascular disease.
Area of Science:
- Cardiovascular Medicine
- Biochemistry
- Pharmacology
Background:
- Cardiovascular disease is a leading global health concern with limited therapies for unstable plaque.
- High-density lipoprotein (HDL) offers plaque stabilization through cholesterol removal, improved endothelial function, and anti-inflammatory effects.
Purpose of the Study:
- To review non-clinical data supporting CER-001 as a functional high-density lipoprotein (HDL) mimetic.
- To evaluate the potential of CER-001 in stabilizing atherosclerotic plaques.
Main Methods:
- Review of non-clinical studies on CER-001, a novel HDL mimetic.
- Analysis of CER-001's composition: a lipoprotein complex of phospholipid and recombinant human apoA-I.
- Examination of clinical trial data on CER-001's effects on plaque burden and arterial wall thickness.
Main Results:
- Non-clinical data demonstrate CER-001 effectively mimics natural HDL function.
- Clinical trials showed CER-001 improved carotid wall thickness in specific patient groups.
- CER-001 impacted coronary plaque burden in post-acute coronary syndrome patients at a low dose.
Conclusions:
- CER-001 is confirmed as a full high-density lipoprotein (HDL) mimetic based on extensive non-clinical evidence.
- CER-001 demonstrates therapeutic potential for cardiovascular disease by targeting plaque stabilization.
- Further investigation into CER-001's efficacy in managing cardiovascular disease is warranted.
Abstract:
Cardiovascular disease remains the most pressing healthcare issue for the developed world and is becoming so for developing countries. There are no currently approved therapies that can rapidly reduce the burden of unstable, inflamed plaque in the overall coronary vascular bed. High-density lipoprotein (HDL) has multiple actions that could lead to plaque stabilization, such as rapid removal of large quantities of cholesterol from the vasculature through the process of reverse lipid transport, improvement in endothelial function, protection against oxidative damage, and reduction in inflammation. Short-term infusion of HDL-mimetics in animal models as well as in humans has shown promising effects on the plaque size and morphology. Cerenis Therapeutics has developed CER-001, a negatively charged lipoprotein complex consisting of phospholipid and recombinant human apoA-I that mimics the structure and function of natural HDL. Three clinical trials using CER-001 infusions have demonstrated improvements in the carotid wall thickness of patients with familial hypercholesterolaemia and in patients with hypo-alphalipoproteinaemia, as well as an impact on coronary plaque burden measured by intravascular ultrasonography at the lowest tested dose (3 mg/kg) in post-ACS patients. Here, we reviewed the non-clinical data leading to the demonstration that CER-001 is a full HDL mimetic.
More Related Videos
12:48Construction of Cell-based Neurotransmitter Fluorescent Engineered Reporters CNiFERs for Optical Detection of Neurotransmitters In Vivo
Published on: May 12, 2016
14:20High Throughput SiRNA Screening for Chloropicrin and Hydrogen Fluoride-Induced Cornea Epithelial Cell Injury
Published on: June 16, 2018
Related Concept Videos
01:28Preclinical Development: Overview
01:11Clinical Trials: Overview
01:29Clinically Relevant Drug Product Specifications: Methods of Establishment
01:16Clinical Trials
There are four phases in a clinical trial. A phase one...